BioCentury | May 26, 2020
Distillery Therapeutics

Blocking inhibitor of apoptosis proteins in liver cells to treat malaria

...Infectious disease INDICATION: Malaria Targeting IAP, a family of apoptosis-blocking proteins that includes BIRC2 and BIRC3...
...tumor indications. TARGET/MARKER/PATHWAY: Inhibitor of apoptosis (IAP); baculoviral IAP repeat-containing 2 (BIRC2; cIAP1); baculoviral IAP repeat-containing 3 (BIRC3; cIAP2...
...Eliza Hall Institute of Medical Research Inhibitor of apoptosis (IAP) Baculoviral IAP repeat-containing 2 (BIRC2) (cIAP1) Baculoviral IAP repeat-containing 3 (BIRC3) (cIAP2...
BioCentury | Oct 4, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer; leukemia Cell culture, mouse and patient-derived organoid studies identified a benzothiophene-benzothiazole-based BIRC2 inhibitor that could help treat breast cancer and leukemias. Screening of 50,000 small molecules in BIRC2 enzymatic activity assays yielded...
BioCentury | May 25, 2018
Clinical News

MimiVax reports Phase II data for glioblastoma immunotherapy

MimiVax LLC (Buffalo, N.Y.) reported interim data from a Phase II trial in 63 newly diagnosed glioblastoma patients showing that subcutaneous SurVaxM led to a six-month progression-free survival (PFS) rate of 96.3% and a 12-month...
BioCentury | May 11, 2018
Clinical News

Medigene reports Phase I/II data for prostate cancer vaccine

Medigene AG (Xetra:MDG1) said none of five high-risk prostate cancer patients who underwent radical surgery experienced biochemical relapse following vaccination with its DC vaccine targeting prostate-specific antigen (PSA; KLK3) that was generated with a toll-like...
BioCentury | Mar 9, 2018
Financial News

Oxford Vacmedix raises $12.5M series A

Oxford Vacmedix UK Ltd. (Oxford, U.K.) raised $12.5 million on March 6 in a series A round from Cancer Rop Co. Ltd. (KOSDAQ:180400) and undisclosed existing Chinese investors. The company's OVM-100 and OVM-200 are in...
BioCentury | Mar 6, 2018
Financial News

Oxford Vacmedix raises $12.5M series A

Oxford Vacmedix UK Ltd. (Oxford, U.K.) raised $12.5 million in a series A round from Cancer Rop Co. Ltd. (KOSDAQ:180400) and undisclosed existing Chinese investors. The company's OVM-100 and OVM-200 are in preclinical testing to...
BioCentury | Mar 1, 2018
Translation in Brief

A path less traveled

A team from PSL Research University has shown how a nitric oxide (NO)-donating compound steers TNFα signaling away from a pro-survival pathway towards one that promotes death in cancer cells. The findings suggest NO-donors could...
BioCentury | Feb 9, 2018
Clinical News

Immunovaccine reports Phase Ib data of DPX-Survivac plus epacadostat for ovarian cancer

In December, Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF) reported top-line data from 10 evaluable patients with platinum-sensitive or -resistant ovarian cancer in the first dose cohort of a Phase Ib trial showing that subcutaneous DPX-Survivac plus twice-daily...
BioCentury | Dec 22, 2017
Clinical News

Stemline reports additional Phase II data for SL-701 in GBM

In November, Stemline Therapeutics Inc. (NASDAQ:STML) reported additional data from the two-stage Phase II STML-701-0114 trial of SL-701 as a second-line treatment of glioblastoma multiforme (GBM). Data were presented at the Society of Neuro-Oncology meeting...
BioCentury | Sep 13, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Aspergillus Cell culture and mouse studies suggest inhibiting A. fumigatus BIR1 could help treat aspergillosis. In A. fumigatus culture, inhibiting A. fumigatus BIR1 with a tool compound designed to inhibit the protein's human homolog,...
Items per page:
1 - 10 of 57